The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers

Pharmacogenetics and Genomics

Volumn 22, Issue 8, 2012, Pages 598-605

  Cho, Sung Kweon ^a,b   Oh, Eun Sil ^b   Park, Kyungsoo ^a,b   Park, Min Soo ^a,b   Chung, Jae Yong ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

atorvastatin; lipids; pharmacogenetics; pharmacokinetics; UGT1A1; UGT1A3

Indexed keywords

ATORVASTATIN; CREATINE KINASE; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; GLUCURONOSYLTRANSFERASE; HEPTANOIC ACID DERIVATIVE; LACTONE; PYRROLE DERIVATIVE; TUMOR PROTEIN; UDP GLUCURONOSYLTRANSFERASE, UGT1A3; UDP-GLUCURONOSYLTRANSFERASE, UGT1A3;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENETIC LINKAGE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; LACTONIZATION; LIPID BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; BLOOD; GENETIC POLYMORPHISM; GENETICS; LIPID METABOLISM; METABOLISM;

ADULT; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HEPTANOIC ACIDS; HUMANS; LACTONES; LIPID METABOLISM; LIPIDS; MALE; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; PYRROLES;

EID: 84863856272     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283544085     Document Type: Article

References (27)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
2. Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006; 79:532-539. (Pubitemid 43833450)
3. Skottheim IB, Gedde Dahl A, Hejazifar S, Hoel K, Asberg A. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci 2008; 33:317-325.
4. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009; 86:197-203.
5. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 2000; 28:1369-1378.
6. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30:505-512. (Pubitemid 34456970)
7. Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, et al. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 2007; 35:1315-1324. (Pubitemid 47121772)
8. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 2010; 87:65-73.
9. Zhang D, Cui D, Gambardella J, Ma L, Barros A, Wang L, et al. Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos 2007; 35:2270-2280. (Pubitemid 350146214)
10. Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics 2011; 21:495-505.
11. Liu Y, Ramrez J, House L, Ratain MJ. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer 2010; 46:2097-2103.
12. Yamamoto N, Takahashi T, Kunikane H, Masuda N, Eguchi K, Shibuya M, et al. Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 2009; 85:149-154.
13. Chung JY, Cho SK, Oh ES, Lee DH, Lim LA, Jang SB, et al. Effect of HMGCR variant alleles on low-density lipoprotein cholesterol-lowering response to atorvastatin in healthy Korean subjects. J Clin Pharmacol 2012; 52:339-346.
14. Chung J, Cho J, Yu K, Kim J, Oh D, Jung H, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005; 78:342-350. (Pubitemid 41393669)
15. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Ltjohann D, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006; 79: 419-426.
16. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73:554-565. (Pubitemid 37249126)
17. Hall D, Ybazeta G, Destro Bisol G, Petzl Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999; 9:591-599.
18. Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One 2010; 5:e9763.
19. Hubacek JA, Vrablik M. Effect of apolipoprotein E polymorphism on statininduced decreases in plasma lipids and cardiovascular events. Drug Metabol Drug Interact 2011; 26:13-20.
20. Riedmaier S, Klein K, Winter S, Hofmann U, Schwab M, Zanger UM. Paraoxonase (PON1 and PON3) polymorphisms: impact on liver expression and atorvastatin-lactone hydrolysis. Front Pharmacol 2011; 2:41.
21. Knauer MJ, Urquhart BL, Meyerzu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010; 106:297-306.
22. Vladutiu GD, Isackson PJ. SLCO1B1 variants and statin-induced myopathy. N Engl J Med 2009; 360:304.
23. Borucki K, Weikert C, Fisher E, Jakubiczka S, Luley C, Westphal S, et al. Haplotypes in the UGT1A1 gene and their role as genetic determinants of bilirubin concentration in healthy German volunteers. Clin Biochem 2009; 42:1635-1641.
24. Akiyama Y, Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, et al. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol 2008; 19:2089-2090.
25. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24:2237-2244.
26. Innocenti F, Grimsley C, Das S, Ramrez J, Cheng C, Kuttab Boulos H, et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12: 725-733. (Pubitemid 36054939)
27. Innocenti F, Liu W, Chen P, Desai A, Das S, Ratain MJ. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 2005; 15:295-301. (Pubitemid 40676550)